#CTOS23 - Twitter Hashtag

almost 3 years ago

The OSI’s Strategic Advisory Board recently attended #CTOS23 with experts from around the globe, where OSI grant winner Isidro Cortés-Ciriano, PhD, was featured. Learn more about his osteosarcoma study: https://t.co/a1BZGeJ5Wx @emblebi @isidrolauscher

OSInstitute's tweet photo. The OSI’s Strategic Advisory Board recently attended #CTOS23 with experts from around the globe, where OSI grant winner Isidro Cortés-Ciriano, PhD, was featured. Learn more about his osteosarcoma study: https://t.co/a1BZGeJ5Wx @emblebi @isidrolauscher https://t.co/SfRpA4GmeN

1

4

0

235

Omico Australia @OmicoAustralia

almost 3 years ago

Congratulations are in order to our Head of Cohorts Dr Mandy Ballinger, who has received the 2023 Liddy Shriver Early Career Research Award at #CTOS23 in Dublin. This recognition of her pioneering work marks the culmination of years dedicated to #sarcoma genetics and early detection to protect people with Li-Fraumeni syndrome (LFS). Thank you, Mandy, for your outstanding research contributions in the field of sarcoma. We wouldn’t be Team Omico without you.

OmicoAustralia's tweet photo. Congratulations are in order to our Head of Cohorts Dr Mandy Ballinger, who has received the 2023 Liddy Shriver Early Career Research Award at #CTOS23 in Dublin.

This recognition of her pioneering work marks the culmination of years dedicated to #sarcoma genetics and early detection to protect people with Li-Fraumeni syndrome (LFS).

Thank you, Mandy, for your outstanding research contributions in the field of sarcoma. We wouldn’t be Team Omico without you.

2

17

6

0

853

Anna M. Czarnecka @AMCzarnecka

almost 3 years ago · Warsaw

@pawel_sobczuk @NIO_PIB @rutkowskip1972 @katarzynakozak9 @hanicahanica I have to admit that #poster session was really cool during #CTOS #CTOS23 😃🥂 Loooking foreward for next meeting already 💙💚💛

AMCzarnecka's tweet photo. @pawel_sobczuk @NIO_PIB @rutkowskip1972 @katarzynakozak9 @hanicahanica I have to admit that #poster session was really cool during #CTOS #CTOS23 😃🥂 Loooking foreward for next meeting already 💙💚💛 https://t.co/wxR9lMhvVQ

0

5

0

119

ApexOnco @ApexOnco

almost 3 years ago

$DCPH has a new challenger. @ByMadeleineA's take on IDRx data at #CTOS23 https://t.co/o32YUbM9fb $BPMC

0

2

3

1

2K

Alessandra Merlini @merlini_ale

almost 3 years ago

Last but not least - our poster on the generation and characterization of the first patient-derived, radiation-induced breast angiosarcoma cell line. Hope it can foster future preclinical #angiosarcoma research! #sarcoma #CTOS23 @SarcomaUniTo @SilviaBrusco6 @DAmbrosio_MD

merlini_ale's tweet photo. Last but not least - our poster on the generation and characterization of the first patient-derived, radiation-induced breast angiosarcoma cell line. Hope it can foster future preclinical #angiosarcoma research!

#sarcoma #CTOS23
@SarcomaUniTo @SilviaBrusco6 @DAmbrosio_MD https://t.co/lI0FR353qz

1

38

8

3

4K

David Gyorki @davidgyorki

almost 3 years ago

Congrats ⁦@ballingermandy⁩ on your amazing work deservedly recognized with the Liddy Shriver award #ctos23. Has been great to see this work grow in impact over the years.

davidgyorki's tweet photo. Congrats ⁦@ballingermandy⁩ on your amazing work deservedly recognized with the Liddy Shriver award #ctos23. Has been great to see this work grow in impact over the years. https://t.co/unQwb1HXJR

1

18

3

0

707

Anna M. Czarnecka @AMCzarnecka

almost 3 years ago

Trial running in @NIO_PIB in #Warsaw just presented in #Dublin at @ctosociety meeting #CTOS23 #CTOS

0

5

0

440

David Gyorki @davidgyorki

almost 3 years ago

High quality data (as always from ⁦@DCalleMD⁩) quantifying the benefit of surgery in high volume centre (13 cases per year) - distance from black line to red/blue line shows magnitude of benefit. #ctos23

davidgyorki's tweet photo. High quality data (as always from ⁦@DCalleMD⁩) quantifying the benefit of surgery in high volume centre (13 cases per year) - distance from black line to red/blue line shows magnitude of benefit.
#ctos23 https://t.co/OddTE4udhY

0

13

6

0

790

David Gyorki @davidgyorki

almost 3 years ago

Anticipation building in RPS session prior to presentation of first ever data from prospective RESAR registry by Dr Mark Fairweather. #ctos23

0

5

1

0

327

David Gyorki @davidgyorki

almost 3 years ago

Great presentation form Dr Keila Torres of the extraordinary potential of the mass spec pen to guide intraoperative decision making in #sarcoma. #ctos23. Will be eagerly watching this space!

davidgyorki's tweet photo. Great presentation form Dr Keila Torres of the extraordinary potential of the mass spec pen to guide intraoperative decision making in #sarcoma. #ctos23. Will be eagerly watching this space! https://t.co/M7wkfsX310

0

4

0

280

Anna M. Czarnecka @AMCzarnecka

almost 3 years ago · Dublin City

Great #CTOS #CTOS23 evening with Guinness 🍻

1

15

1

0

580

Jon Trent, MD, PhD @JTrentMDPhD

almost 3 years ago

Thank you @ashleighg and program committee #CTOS2023 for organizing an incredible meeting! #ctos23

0

19

0

2K

Sachin Sarcoma Society @SachinSarcoma

almost 3 years ago

We are glad to share the first poster of @SachinSarcoma displayed in the patient advocacy lounge in Dublin Ireland in @ctosociety for the sarcoma community. We thank Dr @samdoc_mamc Sarcoma medical Oncology #AIIMS for support. Thanks @sarcomapatients 4 the opportunity #CTOS23

SachinSarcoma's tweet photo. We are glad to share the first poster of @SachinSarcoma displayed in the patient advocacy lounge in Dublin Ireland in @ctosociety for the sarcoma community. We thank Dr @samdoc_mamc Sarcoma medical Oncology #AIIMS for support. Thanks @sarcomapatients 4 the opportunity #CTOS23 https://t.co/Xnn2JAycfo

0

15

5

0

894

David Gyorki @davidgyorki

almost 3 years ago

Fantastic work from our surgical fellow ⁦@eyal_more⁩ ⁦@PeterMacCC⁩ demonstrating that routine extended mastectomy for primary radiation induced #angiosarcoma provides very good long term disease control even without chemotherapy. #ctos23

davidgyorki's tweet photo. Fantastic work from our surgical fellow ⁦@eyal_more⁩ ⁦@PeterMacCC⁩ demonstrating that routine extended mastectomy for primary radiation induced #angiosarcoma provides very good long term disease control even without chemotherapy. #ctos23 https://t.co/ogzYCsaxlZ

1

23

5

0

2K

Sarcoma UK @Sarcoma_UK

almost 3 years ago

It's the final day of the @ctosociety Annual Meeting in Dublin and it's been a hugely positive experience to learn of the work being done across the world on sarcoma. Together we are making change happen. #ctos2023 #ctos23

Sarcoma_UK's tweet photo. It's the final day of the @ctosociety Annual Meeting in Dublin and it's been a hugely positive experience to learn of the work being done across the world on sarcoma.

Together we are making change happen.

#ctos2023 #ctos23 https://t.co/0ipDhvs37Y

0

23

4

0

2K

David Gyorki @davidgyorki

almost 3 years ago

Strong arguments from ⁦@herbloong⁩ for off label treatment in #sarcoma given the real world lack of access to clinical trials in much of the world. #ctos23

davidgyorki's tweet photo. Strong arguments from ⁦@herbloong⁩ for off label treatment in #sarcoma given the real world lack of access to clinical trials in much of the world. #ctos23 https://t.co/s4GIbvJ1BB

0

28

8

0

1K

Breelyn Wilky, MD 🎗 @breelynwilkyMD

almost 3 years ago

“Access to clinical trials is a luxury…” @herbloong #CTOS23

1

63

15

0

7K

CURE ID @id_cure

almost 3 years ago

Thank you to @sarcomapatients for hosting the advocacy lounge @ctosociety. We have been able to connect and speak with advocates in the sarcoma community #CTOS23 #Sarcoma please reach out if you would like to connect

id_cure's tweet photo. Thank you to @sarcomapatients for hosting the advocacy lounge @ctosociety. We have been able to connect and speak with advocates in the sarcoma community #CTOS23 #Sarcoma please reach out if you would like to connect https://t.co/JaXF3tipTl

0

6

2

0

557

Jon Trent, MD, PhD @JTrentMDPhD

almost 3 years ago

@breelynwilkyMD -Botensilimab and balstilimab in #Sarcoma w 15-29% objective responses, 40%PF @ 6 months in #sarcoma -Overall limited toxicity -Current phase 1 study (C-800-01) is actively enrolling patients in an expansion sarcoma cohort @Agenus_Bio #CTOS2023 #ctos23